肺移植患者痰液培养与药敏试验结果分析

Bacterial culture of sputum from lung transplant recipients and drug sensitivity test

  • 摘要: 目的 分析肺移植患者痰液病原菌培养和药敏试验结果,为临床正确使用抗菌药物提供参考依据。方法选取2013年3月-2015年3月在医院接受肺移植手术治疗96例患者为研究对象,对患者痰液标本采用VITEK-32全自动分析鉴定仪进行病原菌鉴定,用K-B法进行耐药试验,数据采用SPSS 17.0软件进行统计分析。结果 96例肺移植患者的痰液标本中共分离出病原菌110株,其中占多数的病原菌为革兰阴性菌,>55.00%,以嗜麦芽寡养单胞菌、铜绿假单胞菌、大肠埃希菌为主,革兰阳性菌占33.64%,以溶血性葡萄球菌及表皮葡萄球菌居多,真菌占11.00%,以曲霉菌和白色念珠菌为主;嗜麦芽寡养单胞菌、铜绿假单胞菌、大肠埃希菌对亚胺培南/西司他丁耐药率较低,均<26.00%,溶血性葡萄球菌、表皮葡萄球菌对万古霉素耐药率较低,均<20.00%,曲霉菌属、白色念珠菌对氟康唑、伊曲康唑耐药率较低,均<26.00%。结论 临床需根据药敏结果合理选用抗菌药物,以达到有效抗感染及减少耐药性的双重作用,从而提高肺移植受体及器官的存活率。

     

    Abstract: OBJECTIVE To analyze bacterial culture results of sputum from lung transplant recipients and drug sensitivity test results, so as to provide the basis for the proper use of antibiotics in clinic. METHODS A total of 96 cases were selected, who had lung transplant surgery in the hospital from Mar. 2013-Mar. 201. Sputum from patients was cultured for pathogen detection by automatic analysis instrument VITEK-32 and K-B method was used for drug resistant test. SPSS 17.0 was used to give statistic analysis. RESULTS From the 96 cases of lung transplant recipients sputum samples, 110 strains of pathogens were isolated, in which gram-negative bacteria accounted for the most, more than 55%, mainly Stenotrophomonas maltophilia, Pseudomonas aeruginosa and Escherichia coli. Gram-positive bacteria were accounted for 33.64%, mainly Staphylococcus haemolyticus and Staphylococcus epidermidis. Fungi were accounted for 11.00%, mainly Aspergillus and Candida albicans. Drug resistant rates of S. maltophilia, P. aeruginosa and E. coli to imipenem/ cilastatin were low, less than 26.00% averagely. Drug resistant rates of S. haemolyticus and S. epidermidis to vancomycin were low, less than 20.00% averagely, and Aspergillus and C. albicans to fluconazole and itraconazole were low, less than 26.00% in average. CONCLUSION The rational use of antimicrobial agents in clinical needs to be based on drug sensitivity results in order to achieve the dual role of effective anti infection and drug resistance reduction, so as to improve the survival rate of lung transplant recipients and organs.

     

/

返回文章
返回